Molecular and genetic testing has become a game-changer in brain tumor care—shaping diagnosis, guiding treatments and opening doors to new therapies. Once available to a handful of patients, these tests are now rapidly being adopted across the NHS, according to a new study led by Professor Kathreena Kurian at the University of Bristol and the Tessa Jowell Brain Cancer Mission. The findings, published in Neuro-Oncology Practice, mark long-awaited progress in a field that has seen few new treatments in over two decades.
This article was originally published on MedicalXpress.com
